Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP137 + anti-PD-1/PD-L1 in Advanced/Metastatic Solid Tumors
NCT05605496Phase 2Active, not recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of np137 in solid tumor (3 arms), sponsored by Centre Léon Bérard. Primary endpoints: Objective Response Rate at 12 weeks and Progression Free Rate at 12 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
np137
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05605496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605496.